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ABSTRACT: 
 
Biomarkers that are able to identify patients at risk of drug-induced liver injury (DILI) after 
treatment with infliximab could be important in increasing the safety of infliximab use. We 
performed a genetic analysis to identify possible human leukocyte antigen (HLA) associations 
with drug-induced liver injury in European Caucasian users of infliximab in a retrospective study 
of 16 infliximab-DILI patients and 60 matched controls. In infliximab-associated liver injury, 
multiple potentially causal individual HLA associations were observed, as well as possible 
haplotypes. The strongest associated HLA allele was HLA-B*39:01 (P=0.001; odds ratio [OR] 
43.6; 95% confidence interval [CI] 2.8-infinity), which always appeared with another associated 
allele C*12:03 (P=0.032; OR 6.1; 95% CI 0.9-47.4). Other associations were observed with 
HLAs DQB1*02:01 (P=0.007; OR 5.7; 95% CI 1.4-24.8), DRB1*03:01 (P=0.012; OR 4.9; 95% 
CI 1.2-20.5), and B*08:01 (P=0.048; OR 3.4; 95% CI 0.9-13.2), which also appeared together 
whenever present in cases. Additional associations were found with HLA-DPB1*10:01 
(P=0.042; OR 20.9; 95% CI 0.7-infinity) and HLA-DRB1*04:04 (P=0.042; OR 20.9; 95% CI 
0.7-infinity). A strong association with HLA-B*39:01 was identified as a potentially causal risk 
factor for infliximab-induced DILI. Future work should aim to validate this finding and explore 
possible mechanisms through which the biologic interacts with this particular allele. 
 
BACKGROUND: 
 
Infliximab (brand names Inflectra®/Ixifi®/Remicade®/Renflexis®) is a mouse-human chimeric 
monoclonal antibody (mAb) to tumor necrosis factor alpha (TNF-alpha) indicated for use in 
Crohn’s disease, ulcerative colitis, rheumatoid arthritis (in combination with methotrexate), 
psoriatic arthritis, psoriasis, and several other autoimmune conditions [1]. Since its initial 
approval for use as a biologic drug in Crohn’s disease by the US Food and Drug Administration 
(FDA) in 1998, infliximab has been widely used to treat patients with autoimmune diseases. 
However, during clinical trials and in practice, drug-induced liver injury (DILI) has been 
observed amongst infliximab users, driving the FDA to add a hepatotoxicity warning to the 
Remicade® label in December of 2004 [1]. There are multiple case reports of drug-induced 
hepatotoxicity in infliximab users, including reactivation of hepatitis B, leading to outcomes such 
as liver failure, need for liver transplantation, and occasionally, death [2]. Based on a two-year 
prospective study in a homogenous Icelandic population, the frequency of infliximab-induced 
liver injury is reported to be 1 in 148 patients treated [3]. Over a 5-year study period in the same 
population, infliximab induced liver injury was observed at a higher frequency of 1 out of 120 
patients treated [4]. The LiverTox website [5], a collaboration between the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Library of Medicine 
(NLM), assigned infliximab a DILI likelihood score of “A” to indicate “well established cause of 
clinically apparent liver injury.” Two recent studies have reported a distinct biological, clinical, 
and histological phenotype of infliximab DILI [4–6]. 
 Insight into genetic predispositions and the mechanisms underlying infliximab-induced 
hepatotoxicity could identify a susceptible subset of patients who might require closer 
monitoring or may consider alternative therapies. There is evidence that specific human 
leukocyte antigen (HLA) polymorphisms are associated with DILI across a number of unrelated 
drugs [7], although to date, these associations have only been reported with small molecule 
drugs. Using the Vanderbilt University Medical Center (VUMC) BioVU biorepository [8,9] to 
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retrospectively identify cases of infliximab-induced hepatotoxicity, this pharmacogenetic study 
aimed to identify the first known association between HLA variants and DILI caused by a 
biologic drug. 
 
METHODS: 
Patient Identification and Characteristics: 
BioVU Samples: 
 Eleven self-reported Caucasian cases for this retrospective study were identified using 
de-identified clinical data extracted from BioVU by Nashville Biosciences, a subsidiary of 
VUMC established to support translational research. Clinical and genotype data were provided 
from BioVU in accordance with BioVU’s data use policies; subjects provided informed consent 
prior to their inclusion in BioVU [8,9]. Since infliximab is administered via infusion, high-
confidence doses were found in the BioVU’s structured clinical data by comparing infliximab 
prescription code dates with infusion Current Procedural Terminology (CPT) code dates, which 
were later confirmed via manual review of the de-identified clinical notes to provide true 
infliximab exposure timeframes and dosing intervals. Serial liver chemistry values for alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), and serum total bilirubin (BILI) were 
converted to multiples of upper limit of normal (ULN) by dividing by the BioVU assay-specific 
ULN values. Possible cases were identified by selecting for infliximab-exposed patients who 
experienced serum ALT greater than 3x the ULN, serum ALP greater than 2x the ULN, or serum 
BILI values greater than 2x the ULN during infliximab treatment. Additionally, cases were only 
considered if there was evidence of baseline ALT, ALP, and BILI values within normal limits 
prior to infliximab exposure. Clinical information related to subjects meeting these criteria were 
further manually reviewed to exclude competing causes of liver injury via underlying condition 
(e.g. fatty liver disease) or concomitant medications known to elevate liver enzymes (e.g. 6-
mercaptopurine) during the course of therapy.  
 Potential cases meeting the above criteria were then evaluated for likelihood of 
infliximab-induced liver injury by a DILI expert (PBW) [10]. Along with structured data 
describing clinical lab values, dosing intervals, and relevant International Classification of 
Diseases (ICD, 9th and 10th revisions) codes with dates, infliximab-induced liver injury was 
confirmed using de-identified clinical notes from relevant specialists, including hepatologists. 
Only cases deemed “Possible,” “Probable,” or “Definite” were included in this study. 
 
iDILIC Samples: 
 An additional seven Caucasian cases for this study were provided by the International 
Drug-Induced Liver Injury Consortium (iDILIC). The cases were adjudicated according to 
criteria previously described [11] and were recruited from centers in Newcastle, UK, Reykjavik, 
Iceland and Montpellier, France as described in more detail elsewhere [7]. All patients from 
iDILIC experienced ALT greater than 5x the ULN. 
 
Controls: 
In order to achieve sufficient power (80%) to detect meaningful HLA associations in this 
study, we sought to include at least three matched controls per DILI case [12]. The 60 Caucasian 
controls for this study were gathered from BioVU’s de-identified structured clinical data and 
notes. Control candidates were identified as patients who (1) were exposed to infliximab for at 
least 12 months, (2) had multiple lab values with no record of ALT or ALP > 1.5x ULN or BILI 
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> 1x ULN within 6 months pre- or post-infliximab exposure, and (3) had no record of DILI-
related ICD codes. Wherever possible, controls were matched for self-reported ethnicity, 
indication of use, age, sex, and BMI. Cases with unknown indication of infliximab use were 
primarily matched to controls with Crohn’s disease, as this is the most common disease among 
infliximab users available in BioVU. De-identified medical records were then manually reviewed 
to confirm these patients had prolonged infliximab exposure consistent with the structured data. 
 
Genome-wide SNP and HLA analysis: 
Genotyping for genome-wide genotyping association studies (GWAS) of cases and 
controls was performed by Vanderbilt Technologies for Advanced Genomics (VANTAGE, 
Nashville, Tennessee) using the Illumina Human MEGA Ex Vanderbilt platform (N=18 cases, 
N=60 controls). A total of 528,683 single nucleotide polymorphisms (SNPs) passed quality 
control (QC). One control sample was found to have insufficient DNA for accurate genotyping; 
no other samples were excluded for quality issues. Principal components analysis (PCA) was 
used to assess population structure and verify self-reported ethnicities of 18 cases and 59 controls 
prior to inclusion in the study. 
In addition to GWAS genotyping, direct HLA typing was possible for a total of 71 
samples (N=11 cases, N=60 controls) by the Institute for Immunology & Infectious Diseases 
(iiiD, Perth, Australia). Using Illumina next generation sequencing (NGS) of exons 2 and/or 3, 
iiiD was able to resolve the HLA alleles at 4-digit resolution for Class I HLAs A, B and C, as 
well as Class II HLAs DPB1, DQA1, DQB1, and DRB1 for further evaluation. For cases with 
inadequate DNA for direct HLA typing (N=7), HLA profiles at these loci were imputed from 
GWAS data using HIBAG [13] (version 1.4) with the European Illumina Infinium MEGA 
BeadChip prediction model. 
 
Statistical Methods: 
 Power calculations were performed using Quanto [14] (version 1.2.4). Population 
structure and outlier identification were determined through PCA using the smartPCA program 
from the EIGENSTRAT [15] package (version 3.0). Reported ethnicities were assessed by 
combining the study population with Thousand Genomes Project [16] (1KG) data and 
demonstrating clustering as expected based on principal components. Identity by descent 
calculations and filtering were run using PLINK [17] (version 1.90b6.9) to confirm that samples 
were unrelated. To evaluate HLA variant association with case-control status, R [18] (version 
3.4.0) was used to calculate two-sided p-values, odds ratios (ORs) and confidence intervals (CIs) 
using Fisher’s Exact Test. Given the fairly low number of alleles tested for causal associations 
(N=76), as well as known HLA haplotype associations within homogenous ethnicities 
[13,19,20], no corrections for multiple comparisons were employed in this study and p-values 
below 0.05 were considered significant. Secondary to HLA associations, GWAS associations 
were also explored using PLINK and a genotypic Fisher’s Exact Test with a genome-wide 
significance threshold of 5.0 x 10-8. Differences in clinical characteristics between cases and 
controls were tested in R using Fisher’s Exact Test for discrete variables and the Wilcoxon-
Mann-Whitney test with normal approximation for continuous variables. Population impact 
measures (e.g., sensitivity, specificity, population attributable fraction) were calculated according 
to Tonk et al. [21].   
 
RESULTS: 
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Patient Population: 
 A total of 18 European Caucasian patients with infliximab-DILI were gathered for our 
study. Eleven of these cases were found retrospectively in VUMC’s BioVU, while the other 
seven were recruited through European recruitment centers participating in the iDILIC study. 
Following a principal components analysis, two cases were removed as “outliers” (see 
Supplementary Figure 1). The lone control with insufficient DNA for GWAS genotyping was 
deemed Caucasian based on the directly-typed HLA profile. As shown in Table 1, the majority 
of DILI cases were female (69%). Primary indications for infliximab use among cases included 
Crohn’s disease (44%), psoriatic arthritis (13%), ulcerative colitis (6%), ankylosing spondylitis 
(6%), erythroderma (6%), sarcoidosis (6%), juvenile idiopathic arthritis (6%), or unknown 
(13%). The majority of cases presented with a hepatocellular DILI pattern, and the median time-
to-DILI was approximately 150 days (range: 48-690 days). Mean maximums for ALT, ALP, and 
BILI were 8.89, 1.49, and 9.27 x ULN, respectively. A summary of latency and liver enzyme 
values among cases can be found in Table 2. 
A total of 60 European Caucasian controls found retrospectively in BioVU were used in 
this study. Average body mass index (BMI) was 27.1 (range: 17-41) for cases and 24.6 (range: 
17.2-48.7) for controls, while the average age at the initiation of treatment for cases was 37 years 
(range: 12-60) in cases and 34 years (range: 11-70) in controls. There were significantly more 
controls with underlying Crohn’s disease (P=0.02), and significantly more cases with unknown 
indication of use (P=0.04), which was due to matching unknown indications in cases with 
Crohn’s disease controls.  
 
Genetic Association: 
 GWAS was performed on 16 cases and 59 controls. The results of the GWAS scan did 
not yield any significant SNPs or genomic regions with infliximab-DILI following correction for 
multiple testing (see Supplementary Figure 2).  
A total of 76 unique 4-digit HLA alleles were tested for association with infliximab-
induced liver injury in this study. The strongest association was found among cases with HLA-
B*39:01 (P=0.0014, Odds Ratio [OR] 43.6, 95% Confidence Interval [CI] 2.82-Infinity). Other 
HLA alleles yielding strong signals include DQB1*02:01, DRB1*03:01, C*12:03, DPB1*10:01, 
DRB1*04:04, and B*08:01; the statistics for all significant (P < 0.05) alleles are shown in Table 
3. Further inspection revealed that cases carrying HLA-B*39:01 and HLA-C*12:03 were 
identical, as were cases carrying HLAs DQB1*02:01, DRB1*03:01, and B*08:01 suggesting 
possible causal HLA haplotypes. In the case of the latter haplotype, we also found that cases with 
these alleles also carried HLAs C*07:01 and DQA1*05:01, which were not significant when 
tested for individual presence (see Supplementary Table 1). The seven significant alleles were 
also reviewed among cases with the most significant liver injury (ALT > 5x ULN, N = 10), and 
all but HLAs DRB1*03:01 and B*08:01 remained significant at P < 0.05 (see Supplementary 
Table 2). 
 The population-level carriage frequencies of each of the top HLA alleles according to 
reference studies in the Allele Frequency Net Database [22,23] (AFND) are reported in Table 4. 
Wherever possible we used the USA National Marrow Donor Program (NMDP) European 
Caucasian cohort as a reference population, as the sample size of 1,242,890 subjects is among 
the largest in AFND and we would expect the USA European Caucasian ethnic makeup to best 
match the population structure of our study samples. For alleles or haplotypes where the USA 
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NMDP reference was not available, we substituted other “Caucasoid” study populations (e.g. 
Italian) from AFND. Per AFND, HLA-B*39:01 is present in approximately 2% of Caucasian 
individuals. Additionally, the HLA-B*39:01-C*12:03 haplotype carriage frequency is 1.3% in 
Caucasoid populations.  
 
 
DISCUSSION: 
 
This study, to our knowledge, is the first report of MHC class I and class II alleles 
associated with DILI due to a biologic drug. In a cohort of 16 European ancestry patients who 
developed DILI while being treated with infliximab, the strongest association was observed for 
HLA-B*39:01, which appeared in 25% of our DILI cases but was absent in controls and has a 
carriage frequency of about 2% in Caucasian populations. Among cases with ALT greater than 
5x ULN, HLA-B*39:01 had an even stronger association with a carriage frequency of 30% and 
OR of 56.5. Assuming a population-wide carriage frequency of 2.3% for HLA-B*39:01 among 
Caucasians, an adverse event frequency of 1 in 120 patients, and an odds ratio similar to that 
observed in this study (43.6), we estimate that as few as 6 patients carrying the HLA-B*39:01 
allele would need to avoid treatment with infliximab to prevent one DILI case. If patients were 
screened for this HLA prior to infliximab therapy, we would expect to avoid one DILI case for 
every 267 patients tested. A summary of population impact measures and benefits of 
pharmacogenomics testing can be found in Table 5. 
Beyond individual HLA allele associations, this study also identified multiple possible 
haplotypes associated with infliximab DILI. Interestingly, we observed that all DILI cases 
carrying HLA-B*39:01 also carried HLA-C*12:03, each of which on its own was found to be 
significantly enriched compared to controls. While HLA-C*12:03 was present in controls, no 
controls with HLA-C*12:03 also carried HLA-B*39:01. In Caucasian populations, the HLA-
B*39:01-C*12:03 haplotype is reported to appear at a frequency of 1.3%, but was observed at a 
rate of 25% in infliximab DILI cases (see Table 4).  
Another possible haplotype association was observed among the five HLA alleles 
B*08:01, C*07:01, DRB1*03:01, DQA1*05:01 and DQB1*02:01, three of which were found to 
be significantly enriched in infliximab DILI cases on an individual level (see Table 3). This 5-
allele haplotype was observed in 7/16 (44%) cases, but was present in only 7/60 (12%) matched 
controls. Although this particular haplotype is not reported explicitly in the AFND database, 
subsets of these alleles consistently appear at a rate of 13-16% (see Supplementary Table 3). 
There are previous reports of HLA haplotypes conferring risk for DILI [24–26], so the 
haplotypes observed in this study should continue to be considered in future work. 
While preliminary and limited by a small number of infliximab-induced DILI cases, there 
appears to be a strong association between carriers of HLA-B*39:01 and developing DILI. Since 
HLA-B*39:01 appears across multiple indications (CD, erythroderma, NA) and is totally absent 
among matched controls, there is little reason to believe that this finding is an artifact of a 
genetic link to underlying indications.   
We are continuing to collect information on infliximab-induced DILI patients in order to 
build a replication cohort in which to validate these findings. Additionally, we are interrogating 
the molecular mechanisms by which HLA alleles may interact with infliximab and thus cause 
hepatotoxicity. Validation of these findings in a replication cohort and elucidation of the 
mechanisms behind this phenomenon could allow for the identification of patients at risk of 
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developing infliximab-induced DILI and proactive alteration of their treatment regimens to avoid 
this adverse event. 
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Table Legends: 
 
Table 1: * Presented as mean and standard deviation. ** Significant at P < 0.05. Abbreviations: 
BMI, body mass index; CD, Crohn's disease; UC, ulcerative colitis; AS, ankylosing spondylitis; 
JIA, juvenile idiopathic arthritis. 
 
Table 2: * Time to DILI reported as median (range); ** One cholestatic case experienced DILI 
after dose increase; Time to DILI: length of time from taking the first infliximab dose until the 
first DILI-qualifying lab value; R-Value: calculated by dividing max ALT (xULN) by max ALP 
(xULN). 
 
Table 3: * Calculated using Fisher’s Exact Test. Calculations for OR involving a 0 were 
recalculated after adding 0.5 to each cell in the contingency matrix. 
 
Table 4: * Carriage frequency calculated from allele frequency assuming Hardy-Weinberg 
Equilibrium. Abbreviations: AFND, Allele Frequency Net Database; NMDP, National Marrow 
Donor Program. 
 
Table 5: Abbreviations: CI, confidence interval; PPV, positive predictive value; NPV, negative 
predictive value; PAF, population attributable fraction; NNT, number needed to treat; NNG, 
number needed to genotype. 
Characteristic: N % N % P-Value Test
Sex Female 11 69% 46 77% 0.53 Fisher's Exact Test
Male 5 31% 14 23%
BMI* 27.1 7.1 24.6 6 0.16 Wilcoxon test
Age* 37 17 34 16 0.61 Wilcoxon test
Indication CD** 7 44% 46 77% 0.02 Fisher's Exact Test
Psoriatic Arthritis 2 13% 4 7% 0.60
UC 1 6% 6 10% 1.00
AS 1 6% 2 3% 0.51
Erythroderma 1 6% 0 0% 0.21
Sarcoidosis 1 6% 1 2% 0.38
JIA 1 6% 1 2% 0.38
Not Available** 2 13% 0 0% 0.04
Table 1: Clinical Characteristics of Cases and Controls
Cases (N=16) Controls (N=60)
DILI Pattern N
Time to DILI 
(days)*
Max ALT
(xULN)
Max ALP 
(xULN)
Max BILI 
(xULN)
R-Value
All cases 16 150 (48-690) 8.89 (7.97) 1.49 (1.69) 9.27 (11.35) 9.44 (7.66)
Hepatocellular 12 140 (48-605) 10.64 (8.41) 0.91 (0.69) 10.09 (11.52) 12.02 (7.07)
Cholestatic 3 180 (141-690)** 3.57 (3.74) 4 (2.66) 8.8 (14.03) 0.76 (0.32)
Mixed 1 225 3.83 0.85 0.80 4.51
Table 2: Mean (standard deviation) of DILI Latency and Clinically Relevant Lab Values
Present Absent Present Absent
HLA-B*39:01 4 12 0 60 0.001 43.6 (2.8 - Inf)
HLA-DQB1*02:01 7 9 7 53 0.007 5.7 (1.4 - 24.8)
HLA-DRB1*03:01 7 9 8 52 0.012 4.9 (1.2 - 20.5)
HLA-C*12:03 4 12 3 57 0.032 6.1 (0.9 - 47.4)
HLA-DPB1*10:01 2 14 0 60 0.042 20.9 (0.7 - Inf)
HLA-DRB1*04:04 2 14 0 60 0.042 20.9 (0.7 - Inf)
HLA-B*08:01 7 9 11 49 0.048 3.4 (0.9 - 13.1)
Table 3: Significant HLA Allele Associations
Allele Cases (N=16) Controls (N = 60) P-Value* Odds Ratio
(95% Confidence Interval)*
DILI Case Control AFND Reference Reference Population Population Size
HLA-B*39:01 25.0 0.0 2.3* USA NMDP European Caucasian 1,242,890
HLA-DQB1*02:01 43.8 11.7 31.6 Italy Central 380
HLA-DRB1*03:01 43.8 13.3 22.8* USA NMDP European Caucasian 1,242,890
HLA-C*12:03 25.0 5.0 9.5* USA NMDP European Caucasian 1,242,890
HLA-DPB1*10:01 12.5 0.0 2.6* USA Caucasian pop 5 268
HLA-DRB1*04:04 12.5 0.0 7.6* USA NMDP European Caucasian 1,242,890
HLA-B*08:01 43.8 18.3 21.6* USA NMDP European Caucasian 1,242,890
HLA-B*39:01  + HLA-C*12:03 25.0 0.0 1.3 Italy pop 5 975
Table 4: Population Frequencies of Significant HLA Alleles
Allele
Carriage Frequency (%) AFND Reference
Allele Odds Ratio (95% CI) Sensitivity Specificity PPV NPV PAF NNT NNG
HLA-B*39:01 43.6 (2.8 - Inf) 46.2% 98.1% 16.7% 99.5% 45% 6 267
HLA-DQB1*02:01 5.7 (1.4 - 24.8) 72.2% 68.7% 1.9% 99.7% 59% 64 202
HLA-DRB1*03:01 4.9 (1.2 - 20.5) 58.8% 77.5% 2.1% 99.6% 47% 59 257
HLA-C*12:03 6.1 (0.9 - 47.4) 38.4% 90.7% 3.4% 99.4% 32% 36 375
HLA-DPB1*10:01 20.9 (0.7 - Inf) 33.3% 97.7% 10.7% 99.4% 32% 10 380
HLA-DRB1*04:04 20.9 (0.7 - Inf) 61.6% 92.9% 6.8% 99.7% 58% 16 205
HLA-B*08:01 3.4 (0.9 - 13.1) 48.0% 78.6% 1.9% 99.4% 34% 77 356
Table 5: Population Impact Measures for Top HLA Associations
Figure Legends: 
 
Supplementary Figure 1: Plot of principal component 1 vs. principal component 2 for 18 cases 
and 59 controls gathered for the study as calculated by smartPCA program of EIGENSTRAT 
package. Two cases were removed as outliers. 
 
 
Supplementary Figure 2: Manhattan plot displaying the association results of infliximab-DILI 
cases (n = 16) vs. matched controls (n = 59). No SNPs are significant at 5 x 10-8. 
 
 
Table Legends: 
 
Supplementary Table 2: * Calculated using Fisher’s Exact Test. Calculations for OR involving a 
0 were recalculated after adding 0.5 to each cell in the contingency matrix. 
 
 
Supplementary Table 3: Key: 1 indicates allele presence in Reference haplotype, 0 indicates 
absence in haplotype per row. 


Present Absent Present Absent
HLA-C*07:01 7 9 14 46 0.124 2.5 (0.7 - 9.3)
HLA-DQA1*05:01 7 9 27 33 1.00 1 (0.3 - 3.3)
Supplementary Table 1: Statistics for HLA-C*07:01 and HLA-DQA1*05:01
Allele
Cases (N=16) Controls (N = 60)
P-Value
Odds Ratio
(95% Confidence Interval)
Present Absent Present Absent
HLA-B*39:01 3 7 0 60 0.002 56.5 (2.8 - Inf)
HLA-DQB1*02:01 4 6 7 53 0.044 4.9 (0.8 - 27.5)
HLA-DRB1*03:01 4 6 8 52 0.061 4.2 (0.7 - 23)
HLA-C*12:03 3 7 3 57 0.034 7.7 (0.9 - 70)
HLA-DPB1*10:01 2 8 0 60 0.019 35.6 (1.2 - Inf)
HLA-DRB1*04:04 2 8 0 60 0.019 35.6 (1.2 - Inf)
HLA-B*08:01 4 6 11 49 0.205 2.9 (0.5 - 14.9)
Supplementary Table 2: Significant HLA Allele Associations in Cases with ALT > 5x ULN
Allele Cases (N=10) Controls (N = 60) P-Value* Odds Ratio
(95% Confidence Interval)*
HLA-B*08:01 HLA-C*07:01 HLA-DRB1*03:01 HLA-DQA1*05:01 HLA-DQB1*02:01 Ref Freq Ref Sample Size Reference Pop
1 1 1 0 1 13.7% 250 Ireland South
0 0 1 1 1 13.1% 1,899 USA European American
0 0 1 1 1 14.4% 220 USA San Francisco Caucasian
1 1 0 0 0 16.0% 1,000 Ireland Northern
1 1 0 0 0 10.8% 265 USA Caucasian pop 2
1 1 1 1 1 43.8% 16 INF Cases
1 1 1 1 1 11.7% 60 INF Controls
1 1 1 1 1 18.4% 76 INF Total
Supplementary Table 3: Haplotype Frequencies in AFND References
